There are currently 651 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
NCT05403541
Recruiting
The purpose of this 4-period study is to confirm the efficacy and safety of batoclimab in participants with gMG. In Period 1, participants will be randomized 1:1:1 to receive batoclimab 680 milligrams (mg) subcutaneously (SC) once a week (QW) or 340 mg SC QW or placebo. The primary efficacy endpoint will be assessed by change in the myasthenia gravis activities of daily living (MG- ADL) score in acetylcholine receptor antibody seropositive (AChRAb+) participants. In Period 2, participants previo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Site Number - 1030, Charleston, South Carolina
Conditions: Generalized Myasthenia Gravis
Register for Updates
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542
Recruiting
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina
Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Register for Updates
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT05011305
Recruiting
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US015, Charleston, South Carolina +1 locations
Conditions: Nonalcoholic Steatohepatitis, Fibrosis
Register for Updates
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
NCT04094818
Recruiting
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin & soft tissue infections; or suspected sepsis of any cause.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection, Sepsis, Suspected Meningitis/Encephalitis or Any Other Infection
Register for Updates
Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD
NCT04591392
Recruiting
Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with clinically significant secundum atrial septal defect
Gender:
All
Ages:
84 years and below
Trial Updated:
12/21/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/20/2023
Locations: Roper St. Francis Physician Partners - Breast Surgery, Charleston, South Carolina
Conditions: Breast Cancer
Register for Updates
Treatment of Depression Post-SCI
NCT04263285
Recruiting
Depression is more common after a spinal cord injury (SCI) than in the general population. Unfortunately, it is unknown how depression is typically treated in individuals with SCI or if commonly used treatment methods are effective. This study will investigate the safety and impact of a novel method for treating depression called repetitive transcranial magnetic stimulation (rTMS). rTMS is a type of non-invasive brain stimulation. Fourteen individuals with a cervical or thoracic level SCI and de... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
12/20/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Depression, Spinal Cord Injuries
Register for Updates
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
NCT04970901
Recruiting
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/19/2023
Locations: Hollings Cancer Center, Charleston, South Carolina
Conditions: B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
All
Ages:
All
Trial Updated:
12/17/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
NCT03642028
Recruiting
Post-traumatic stress disorder (PTSD) is a common consequence of combat that can result in trauma-related hyperarousal and sleep disturbances. Poor sleep, one of the most common complaints in Veterans with PTSD, can be distressing, impair concentration and memory, and contribute to physical health conditions, such as metabolic syndrome, inflammation, and cardiovascular disease. The orexin neuropeptide system underlies both sleep and stress reactivity. Suvorexant, a drug that reduces orexin, impr... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/13/2023
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Register for Updates
Prospective Study of Pregnancy in Women With Cystic Fibrosis
NCT04828382
Recruiting
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
Gender:
Female
Ages:
16 years and above
Trial Updated:
12/12/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pregnancy Related, Cystic Fibrosis
Register for Updates
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
NCT05766943
Recruiting
This study is enrolling participants who are already implanted with a S-ICD device ( subcutaneous ICD), and are undergoing a routine outpatient clinic follow up appointment to have their S-ICD checked. The aim of the study is to see if a feature in the device can recognize muscle movement and differentiate movement from irregular heart signals. The study involves doing some simple arm exercises while collecting device data, both with this feature turn on and then with it turned off. Participants... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Subcutaneous ICD, Myopotential Interference
Register for Updates